Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus ...

Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change-up in its R&D focus. | Theriva ...

If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042. The company issued $4m in ordinary shares and additionally agreed ...

RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade ...

Strasbourg (France), March 11, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today ...

This funding will enable Valo to expand and complete the Phase 1B clinical study of the company's lead tumour antigen-coated ...

Jackson highlights Calidi's novel stem cell-based technology, designed to protect, amplify, and potentiate oncolytic viruses, enabling a more effective and targeted attack on cancer cells.